Data Sheet (Cat.No.TMPK-00806)

TargetMol

GHR/Growth Hormone R Protein, Human, Recombinant (His)

General Information

Synonyms:	GHR/BP;GH receptor;GHBP;GHR
Protein Construction:	Ala27-Tyr264
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P10912-1
Molecular Weight:	28.8 kDa (predicted). Due to glycosylation, the protein migrates to 45-60 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1 EU/μg by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Shipping:

In general, Lyophilized powders are shipping with blue ice.

Protein Background

Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a "moonlighting" protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus.

Reference

Lan H, et al. Endocytosis and Degradation of Pegvisomant and a Potential New Mechanism That Inhibits the Nuclear Translocation of GHR. J Clin Endocrinol Metab. 2019 Jun 1;104(6):1887-1899. doi: 10.1210/jc.2018-02063. PMID: 30602026.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481